ArticleTherapeutic drug monitoring2026
Broad-Spectrum Drug Screening Positivity Rates in Pediatrics and Adults: The Reference Laboratory Perspective.
Article in Therapeutic drug monitoring, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBroad-spectrum drug testing is useful in various practical settings, especially when patients present with unknown exposures. Although national poison control data inform trends in toxicity and poison control calls, a need exists for clinical drug detection data across different patient populations.
methodsTo address this need, this retrospective study analyzed drug positivity rates from plasma and urine samples tested on a 127-analyte broad-spectrum drug panel. Samples were stratified by sex and age groups (pediatric <18 years, adult ≥18 years). Positivity rates for drug classes and copositivity patterns were compared using χ 2 testing with Bonferroni correction.
resultsIn total, 7750 samples (3140 plasma and 4610 urine) were analyzed. Positivity for at least one of the tested analytes was high (86% in plasma and 82% in urine). In urine, significant differences in positivity rates between male and female patients were observed for anticonvulsants, antidepressants, antihistamines, benzodiazepines, muscle relaxants, and nicotine. All substances were more prevalent in female patients, except nicotine. Copositivity was more common in female patients, who were more likely than male patients to test positive for 2 or more drug classes. Pediatrics were more likely than adults to test positive for sedatives but less likely for most other drug classes. Overall, patterns of drug class detection differed significantly by age and sex.
conclusionsThis retrospective study reports real-world positivity patterns in a broad-spectrum drug panel, including significant sex- and age-based differences. The higher rates of copositivity in female patients and the higher prevalence of sedatives in pediatric patients are clinically relevant for interpreting drug screen results and managing acute toxidromes. These findings may be useful to both acute care decision making and public health policy interventions, particularly in the pediatric setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.